Life Sciences

Life Sciences

life sciences industry

As part of one of the world’s leading life sciences practices, Ropes & Gray’s Tokyo attorneys have extensive background in international life sciences transactions matters.

Often working for the largest or more promising global pharmaceutical and biotechnology clients, attorneys in our Tokyo office regularly advise clients on international licensing, joint ventures, mergers and acquisitions and product and IP protection strategies.  They are part of our group widely recognized for the ability to help life sciences clients grow and protect their global businesses. 

Recent matters include:

  • Representing a major Japanese pharmaceutical company in defending against alleged drug-pricing violations.
  • Structuring strategic supply and international licensing arrangements for a leading Japanese pharmaceutical company.
  • Helping a Japanese pharmaceutical company develop and execute on an Orange Book and ANDA litigation strategy for one of their key compounds.
  • Advising a Japanese pharmaceutical company on its clinical trial practices and patient data handling techniques.
  • Acting for Johnson & Johnson in numerous transactions, including:
    • its co-promotion agreement with Takeda Pharmaceutical Company granting Takeda the right to co-promote VELCADE(R) (bortezomib) for injection, a treatment for patients with multiple myeloma, in Japan.
    • its collaboration agreement with Takeda to co-market Galantamine in Japan for the treatment of Alzheimer’s disease once Johnson & Johnson affiliate’s application is approved by Japan’s regulatory authorities.
    • its license and co-promotion agreement with Millennium Pharmaceuticals for Velcade; the spinout of Macroflux Corporation from its subsidiary Alza Corporation.
    • the spinout of multiple GUI pharmaceutical product portfolios to Movetis N.V. from its Belgian subsidiary Janssen Pharmaceutical N.V.
    • its influenza vaccine collaboration and investment in Crucell N.V.
  • Advising China Medical Technologies, a leading NASDAQ-listed, Beijing-based medical device company, in its $175 million acquisition of Fluorescent in situ Hybridization (FISH) technology for the diagnosis of prenatal and postnatal disorders and various cancers. We also advised China Medical Technologies on its $345 million purchase of the rights for a HPV-DNA Biosensor Chip and Surface Plasmon Resonance-based Analysis System (SPR System), which can detect the virus that causes cervical cancer and sexually transmitted disorders.
  • Representing Genzyme in connection with the structuring, negotiation and drafting of a $2.9 billion in-license and asset acquisition from Bayer Schering Pharma AG, in which Genzyme acquired from Bayer, among other things, worldwide rights to Campath, Fludara, and Leukine, each currently approved for an oncology indication.